This Article Full Text Full Text (PDF) All Versions of this Article: 40/5/1549    most recent STROKEAHA.108.537084v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Di Napoli, M. Articles by Singh, P. Search for Related Content PubMed PubMed Citation Articles by Di Napoli, M. Articles by Singh, P. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Arterial thrombosis Acute Cerebral Infarction Genetics of Stroke Related Article

(Stroke. 2009;40:1549.)
© 2009 American Heart Association, Inc.

Editorials

Is Plasma Fibrinogen Useful in Evaluating Ischemic Stroke Patients?

Why, How, and When

Mario Di Napoli, MD Puneetpal Singh, PhD

From the Neurological Service (M.D.N.), San Camillo de’ Lellis General Hospital, Rieti, Italy; and the Molecular Genetics Laboratory (P.S.), Department of Human Biology, Punjabi University, Patiala, India.

Correspondence to Dr Mario Di Napoli, Neurological Section, SMDN—Center for Cardiovascular Medicine and Cerebrovascular Disease Prevention, Via Trento, 41, I-67039–Sulmona (AQ), Italy. E-mail mariodinapoli@katamail.com

Key Words: fibrinogen • risk factor • cerebrovascular disease • inflammation • outcome • prognosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

See related article, pages 1687–1691.

In this issue of Stroke, del Zoppo et al¹ report new data on the association between hyperfibrinogenemia and functional prognosis after ischemic stroke using the placebo data from 2 well-known clinical interventional trials on the use of defibrinogenating agent ancrod in acute ischemic stroke.^2,3 Briefly, the authors explore the relationship of fibrinogen with the ischemic stroke outcome showing that patients with lower initial fibrinogen levels (<4.5 g/L) had better functional outcomes even when corrected for age and initial stroke severity.¹ They confirmed a relationship between fibrinogen and prognosis independent of other cardiovascular risk factors and stroke severity.^4,5

Because patients at risk for the development of fibrinogen-related ischemic complications of atherosclerosis can be easily identified and nonpharmacological treatment (cessation of smoking, diet, exercise) seems to lower raised fibrinogen levels together with several drugs (fibrates, ₃ fatty acids, ticlopidine, pentoxifylline, defibrotide),⁶ clinically oriented secondary prevention recommendations⁷ should consider the role of fibrinogen in ischemic stroke. The clinical use of fibrinogen measurement should be based on (1) evidence regarding the ability of fibrinogen to predict ischemic stroke prognosis beyond that of current prognostic prediction methods or models, and (2) evidence regarding the use of prognosis prediction to treatment of ischemic stroke.⁶

A large body of well-done studies demonstrates an association between fibrinogen levels and ischemic stroke prognosis.^1,4,5,8–18 There are, however, uncertainties in the exact role that fibrinogen plays in the determining ischemic stroke prognosis and the reliability of fibrinogen assessment. Because fibrinogen concentrations remain associated with ischemic . . . [Full Text of this Article]

Related Article:

Hyperfibrinogenemia and Functional Outcome From Acute Ischemic Stroke

Gregory J. del Zoppo, David E. Levy, Warren W. Wasiewski, Arthur M. Pancioli, Andrew M. Demchuk, James Trammel, Bart M. Demaerschalk, Markku Kaste, Gregory W. Albers, and Eric B. Ringelstein
Stroke 2009 40: 1687-1691. [Abstract] [Full Text] [PDF]